NEW YORK (GenomeWeb) – Definiens announced today that Takeda Pharmaceuticals will use its new cloud-based digital pathology platform in its translational and biomarker research.

When combined with deeply researched biomarker analysis, Definiens said its new platform, VeriTrova, can help translate biomarker research into the clinic through a new generation of diagnostics. Takeda, an early adopter of the platform, plans to use it for comprehensive tissue-based analysis in its clinical trials, and to support its clinical biomarker development programs.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.